Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas Meeting Abstract
| Authors: | Reed, D. R.; Chawla, S. P.; Setty, B.; Mascarenhas, L.; Meyers, P. A.; Metts, J.; Harrison, D. J.; Lessnick, S. L.; Crompton, B. D.; Loeb, D.; Stenehjem, D. D.; Wages, D. S.; Santiesteban, D. Y.; Mirza, N. Q.; DuBois, S. G. |
| Abstract Title: | Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120306168 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.TPS11577 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS11577 -- Source: Wos |
